<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529123</url>
  </required_header>
  <id_info>
    <org_study_id>INSLIL08556</org_study_id>
    <secondary_id>U1111-1200-1162</secondary_id>
    <nct_id>NCT03529123</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)</brief_title>
  <official_title>A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal Insulin With or Without Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination&#xD;
      (FRC) to insulin glargine by demonstrating change in glycosylated hemoglobin (HbA1c).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the effects of the FRC in comparison with insulin glargine on:&#xD;
&#xD;
        -  Percentage of patients reaching HbA1c targets (&lt;7% );&#xD;
&#xD;
        -  Glycemic control in relation to a meal as evaluated by 2-hour Post-prandial Plasma&#xD;
           Glucose; (PPG);&#xD;
&#xD;
        -  Body weight&#xD;
&#xD;
        -  Fasting Plasma Glucose (FPG);&#xD;
&#xD;
        -  Percentage of patients reaching HbA1c targets of &lt;7% with no body weight gain and no&#xD;
           hypoglycemia (as defined in the evaluation criteria);&#xD;
&#xD;
        -  7-point Self-Monitoring Plasma Glucose (SMPG) profile;&#xD;
&#xD;
        -  Insulin glargine dose.&#xD;
&#xD;
        -  To assess the safety and tolerability in each treatment group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum study duration per patient is 33 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">November 25, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Mean change in glycosylated hemoglobin (HbA1c) from baseline to Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with HbA1c &lt;7%</measure>
    <time_frame>At Week 24</time_frame>
    <description>Number of patients reaching HbA1c &lt;7 % at the end of Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-hour Post prandial glucose (PPG)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Change in 2-hour PPG from baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Change in body weight from baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with HbA1c &lt;7% with no body weight gain and no hypoglycemia</measure>
    <time_frame>At Week 24</time_frame>
    <description>Number of patients reaching HbA1c &lt;7% with no body weight gain and no hypoglycemia at the end of Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Mean change in FPG from baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>Up to 33 weeks</time_frame>
    <description>Number of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with HbA1c &lt;7% with no body weight gain</measure>
    <time_frame>At Week 24</time_frame>
    <description>Number of patients reaching HbA1c &lt;7% with no body weight gain at the end of Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SMPG profiles</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Change in 7-point self-monitoring plasma glucose (SMPG) profiles from baseline to Week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Tested Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine/lixisenatide fixed ratio combination (FRC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine (Lantus®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)</intervention_name>
    <description>Pharmaceutical form: Injection&#xD;
Route of administration: Subcutaneous</description>
    <arm_group_label>Tested Drug</arm_group_label>
    <other_name>Soliqua, Insulin Glargine/Lixisenatide Fixed Ratio Combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE (HOE901)</intervention_name>
    <description>Pharmaceutical form: Injection&#xD;
Route of administration: Subcutaneous</description>
    <arm_group_label>Control Drug</arm_group_label>
    <other_name>Lantus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Pharmaceutical form: Tablet&#xD;
Route of administration: Oral</description>
    <arm_group_label>Control Drug</arm_group_label>
    <arm_group_label>Tested Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine (HMR1964)</intervention_name>
    <description>Pharmaceutical form: Injection&#xD;
Route of administration: Subcutaneous</description>
    <arm_group_label>Control Drug</arm_group_label>
    <arm_group_label>Tested Drug</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Patients with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the&#xD;
             screening visit,&#xD;
&#xD;
          -  At screening:&#xD;
&#xD;
          -  Age should be ≥ 18 years of age to &lt; 65 years;&#xD;
&#xD;
          -  Glycosylated hemoglobin (HbA1c) at screening visit ≥ 7.5% or ≤ 10%;&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 19 kg/m2 and ≤ 40 kg/m2.&#xD;
&#xD;
          -  Patients who have been treated with a basal insulin for at least 6 months before the&#xD;
             screening visit, and who have been on a stable basal insulin regimen (ie, type of&#xD;
             insulin and time/frequency of the injection), for at least 3 months before the&#xD;
             screening visit. The stable total daily dose should be within the range of 15-40 U,&#xD;
             both inclusive, on the day of screening, but individual fluctuations of ± 20% within 2&#xD;
             months prior to screening are acceptable.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Use of oral or injectable glucose-lowering agents other than those stated in the&#xD;
             inclusion criteria in the 3 months before screening.&#xD;
&#xD;
          -  Previous use of insulin regimen other than basal insulin eg, prandial or pre-mixed&#xD;
             insulin (Note: Short term treatment due to intercurrent illness including gestational&#xD;
             diabetes is allowed at the discretion of the investigator).&#xD;
&#xD;
          -  For patients taking metformin, any contraindication to metformin use, according to&#xD;
             local labeling.&#xD;
&#xD;
          -  For patient not treated with metformin at screening: severe renal function impairment&#xD;
             with an estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73m2 or end-stage&#xD;
             renal disease.&#xD;
&#xD;
          -  Personal or immediate family history of medullary thyroid cancer (MTC) or genetic&#xD;
             condition that predisposes to MTC (eg, multiple endocrine neoplasia syndromes).&#xD;
&#xD;
          -  Clinically relevant history of gastrointestinal disease associated with prolonged&#xD;
             nausea and vomiting, including (but not limited to): gastroparesis, unstable (ie,&#xD;
             worsening) or not controlled (ie, prolonged nausea and vomiting) gastroesophageal&#xD;
             reflux disease requiring medical treatment, within 6 months prior to the time of&#xD;
             screening visit; or history of surgery affecting gastric emptying.&#xD;
&#xD;
          -  History of pancreatitis (unless pancreatitis was related to gallstones and&#xD;
             cholecystectomy has been performed), pancreatitis during previous treatment with&#xD;
             incretin therapies, chronic pancreatitis, pancreatectomy.&#xD;
&#xD;
          -  Average insulin glargine daily dose &lt;20 U or &gt;50 U calculated for the last 3 days&#xD;
             before Visit 6.&#xD;
&#xD;
          -  Amylase and/or lipase &gt;3 upper limit normal (ULN) at Visit 5 (Week -1).&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 01</name>
      <address>
        <city>Bangalore</city>
        <zip>560092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 012</name>
      <address>
        <city>Belgaum</city>
        <zip>590010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 013</name>
      <address>
        <city>Chennai</city>
        <zip>600086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 017</name>
      <address>
        <city>Coimbatore</city>
        <zip>641009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 06</name>
      <address>
        <city>Hyderabad</city>
        <zip>500063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 07</name>
      <address>
        <city>Hyderabad</city>
        <zip>500072</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 08</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 04</name>
      <address>
        <city>Kolkata</city>
        <zip>700107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 018</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 014</name>
      <address>
        <city>Madurai</city>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 05</name>
      <address>
        <city>Nasik</city>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 010</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 016</name>
      <address>
        <city>Pune</city>
        <zip>411040</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

